Treat-and-Extend Regimen for Diabetic Macular Edema: Real-World Outcomes and Predictive Factors for Treatment Interval Extension

Purpose To evaluate the real-world effectiveness of a TReat and EXtend (TREX) regimen with anti-vascular endothelial growth factor (anti-VEGF) agents in diabetic macular edema (DME) and identify predictors of treatment interval extension.Methods This retrospective single-center study included treatment-naive DME eyes receiving three loading doses of intravitreal bevacizumab followed by TREX treatment with ranibizumab or aflibercept. Best corrected visual acuity (BCVA), central macular thickness, injection numbers, and maximum treatment interval (Tremax) were analyzed over 48 months. Optical coherence tomography biomarkers were evaluated as predictors of Tremax.Results A total of 224 eyes were included. Mean BCVA gains were 10.9 ± 21.1, 11.17 ± 20.64, 14.08 ± 21.40, and 17.12 ± 23.48 ETDRS letters at months 12, 24, 36, and 48, respectively. A Tremax ≥12 weeks was achieved in 57.1% of eyes. Eyes with Tremax <12 weeks had worse baseline BCVA (0.73 ± 0.60 vs. 0.57 ± 0.61 logMAR; p = .005), a higher prevalence of hyperreflective dots (HRD) (52.2% vs. 25.0%; p = .001), and more subfoveal hard exudates (37.0% vs. 20.8%; p = .015). One case each of endophthalmitis and vitreous hemorrhage occurred.Conclusions In this real-world cohort, TREX with anti-VEGF agents was associated with visual and anatomical improvement over up to 48 months. Worse baseline BCVA, hyperreflective dots, and subfoveal hard exudates were associated with shorter Tremax (<12 weeks).

Authors

Institutions

Publication Details

Journal
Seminars in Ophthalmology
Published
2026-11-21
DOI
https://doi.org/10.1080/08820538.2026.2766552
Primary Topic
Retinal Diseases and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Treat-and-Extend Regimen for Diabetic Macular Edema: Real-World Outcomes and Predictive Factors for Treatment Interval Extension

Nihat Sayın, Mediha Dilek Ozer, Mehmet Erdoğan, Sadık Etka Bayramoğlu et al.
Seminars in Ophthalmology
Retinal Diseases and Treatments
article

Treat-and-Extend Regimen for Diabetic Macular Edema: Real-World Outcomes and Predictive Factors for Treatment Interval Extension

Nihat Sayın, Mediha Dilek Ozer, Mehmet Erdoğan, Sadık Etka Bayramoğlu, İbrahim Koçak, Zeynep Yılmazabdurrahmanoğlu, Sehmus Akpinar, Gulhumar Artis, Mehmet Ozkaya
article en

Abstract

Purpose To evaluate the real-world effectiveness of a TReat and EXtend (TREX) regimen with anti-vascular endothelial growth factor (anti-VEGF) agents in diabetic macular edema (DME) and identify predictors of treatment interval extension.Methods This retrospective single-center study included treatment-naive DME eyes receiving three loading doses of intravitreal bevacizumab followed by TREX treatment with ranibizumab or aflibercept. Best corrected visual acuity (BCVA), central macular thickness, injection numbers, and maximum treatment interval (Tremax) were analyzed over 48 months. Optical coherence tomography biomarkers were evaluated as predictors of Tremax.Results A total of 224 eyes were included. Mean BCVA gains were 10.9 ± 21.1, 11.17 ± 20.64, 14.08 ± 21.40, and 17.12 ± 23.48 ETDRS letters at months 12, 24, 36, and 48, respectively. A Tremax ≥12 weeks was achieved in 57.1% of eyes. Eyes with Tremax <12 weeks had worse baseline BCVA (0.73 ± 0.60 vs. 0.57 ± 0.61 logMAR; p = .005), a higher prevalence of hyperreflective dots (HRD) (52.2% vs. 25.0%; p = .001), and more subfoveal hard exudates (37.0% vs. 20.8%; p = .015). One case each of endophthalmitis and vitreous hemorrhage occurred.Conclusions In this real-world cohort, TREX with anti-VEGF agents was associated with visual and anatomical improvement over up to 48 months. Worse baseline BCVA, hyperreflective dots, and subfoveal hard exudates were associated with shorter Tremax (<12 weeks).

Seminars in Ophthalmology
Sivas State Hospital (TR), Sağlık Bilimleri Üniversitesi (TR), İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi (TR)
Retinal Diseases and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon